Goodwin G.M. et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 2022;387:1637-1648 (PMID 36322843).
Why this study
Our liberty cap card is built on safety, not on "benefit" — but the clinical context around psilocybin needs honest reporting. This is the largest controlled trial at publication: synthetic psilocybin (COMP360) against severe, treatment-resistant depression.
Methods
- Phase 2b, double-blind: 233 adults with treatment-resistant depression (failed ≥2 antidepressants).
- A single dose: 25 mg (n=79), 10 mg (n=75) or 1 mg (control, n=79) — all with mandatory psychological support.
- Primary endpoint: MADRS change at week 3; secondary — ≥50% response and remission ≤10.
Findings
- 25 mg produced a MADRS drop of −12.0 vs −5.4 in controls — a −6.6 difference (p<0.001).
- Response ≥50%: 37% (25 mg) vs 18% (control); remission 29% vs 8%.
- But: by week 12 a sustained response held in only ~20% — the effect often faded.
- Adverse events: headache (24%), nausea (22%), dizziness; in the 25/10 mg arms — cases of suicidal behaviour and self-harm, none in controls.
- The 10 mg dose did not separate from control.
Why it matters — and caveats
This is the strongest 2022 evidence that psilocybin can rapidly reduce severe depression symptoms. But the card is not advocacy:
- The effect waned — by week 12 it had not persisted in most patients.
- Blinding was broken by the drug's own effects (patients knew which arm they were in) — biasing ratings.
- Suicidal events occurred in the treatment arms — why this is done only under medical supervision.
- COMP360 is a synthetic pharmaceutical, not "forest mushrooms"; dose and purity are controlled in ways wild foraging never is.